Sarepta Therapeutics Reaches Settlement Agreement with Regenxbio, UPenn, and Catalent
Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment
Neutral
Importance
7
Price
$19.03
Mkt Cap
$2.002B
52W Low
$14.68
52W High
$25.32
52W Position
30% above low
Off High
25% below high
Rel. Volume
1.1× avg
Market data snapshot near publication time
SRPT sits 30% above its 52-week low of $14.68.
Summary
Sarepta Therapeutics has entered into a settlement agreement with Regenxbio, UPenn Trustees, and Catalent. Under the terms, Sarepta will pay $39 million to Regenxbio within 10 days of the effective date. The resolution addresses a multi-party dispute, removing potential legal and financial uncertainties for the company. Specific terms beyond the payment are not disclosed.
At the time of this announcement, SRPT was trading at $19.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $14.68 to $25.32. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.
Price Chart
SRPT - Latest Insights
SRPT
Sep 30, 2026, 8:30 AM EDT
Price at Filing:
$18.64
Real-time Price:
$18.22
Change:
-$0.420 (-2%)
Market Cap:
$1.925B
SRPT
Jul 27, 2026, 9:08 AM EDT
Price at Filing:
$16.35
Real-time Price:
$18.22
Change:
+$1.87 (+11%)
Market Cap:
$1.925B
SRPT
Jun 30, 2026, 8:36 AM EDT
Price at Filing:
$17.30
Real-time Price:
$18.22
Change:
+$0.920 (+5%)
Market Cap:
$1.925B
SRPT
Jun 04, 2026, 4:29 PM EDT
Price at Filing:
$16.74
Real-time Price:
$18.22
Change:
+$1.48 (+9%)
Market Cap:
$1.925B
SRPT
May 06, 2026, 4:10 PM EDT
Price at Filing:
$21.95
Real-time Price:
$18.22
Change:
-$3.73 (-17%)
Market Cap:
$1.925B